Completed PHASE2 INTERVENTIONAL 1-arm NCT00618982

Sorafenib Dose Escalation in Renal Cell Carcinoma

A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma.

Sponsor: Bayer

Conditions Carcinoma, Renal Cell

Interventions Sorafenib (Nexavar, BAY43-9006)

Updated 6 times since 2017 Last updated: Nov 23, 2015 Started: Feb 29, 2008 Primary completion: Apr 30, 2009 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Renal Cell, this trial is completed. The trial is conducted by Bayer and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aviano, Italy , Bordeaux, France , Cardiff, United Kingdom , Glasgow, United Kingdom , Greater Manchester, United Kingdom , Hanover, Germany , Jena, Germany , La Roche-sur-Yon, France , London, United Kingdom , Mainz, Germany and 11 more locations